LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress.

Studies of Parkinson's disease (PD) have been hindered by lack of access to affected human dopaminergic (DA) neurons. Here, we report generation of induced pluripotent stem cells that carry the p.G2019S mutation (G2019S-iPSCs) in the Leucine-Rich Repeat Kinase-2 (LRRK2) gene, the most common PD-related mutation, and their differentiation into DA neurons. The high penetrance of the LRRK2 mutation and its clinical resemblance to sporadic PD suggest that these cells could provide a valuable platform for disease analysis and drug development. We found that DA neurons derived from G2019S-iPSCs showed increased expression of key oxidative stress-response genes and α-synuclein protein. The mutant neurons were also more sensitive to caspase-3 activation and cell death caused by exposure to stress agents, such as hydrogen peroxide, MG-132, and 6-hydroxydopamine, than control DA neurons. This enhanced stress sensitivity is consistent with existing understanding of early PD phenotypes and represents a potential therapeutic target.

[1]  T. Ichisaka,et al.  Induction of Pluripotent Stem Cells From Adult Human Fibroblasts by Defined Factors , 2008 .

[2]  M. Koch,et al.  Otx2 Regulates Subtype Specification and Neurogenesis in the Midbrain , 2005, The Journal of Neuroscience.

[3]  R. Reijo-Pera,et al.  Isolation and Characterization of Pluripotent Human Spermatogonial Stem Cell-Derived Cells , 2009, Stem cells.

[4]  Peter S. Freestone,et al.  Acute effects of 6-hydroxydopamine on dopaminergic neurons of the rat substantia nigra pars compacta in vitro. , 2005, Neurotoxicology.

[5]  K. Lim,et al.  Parkin Protects against LRRK2 G2019S Mutant-Induced Dopaminergic Neurodegeneration in Drosophila , 2009, The Journal of Neuroscience.

[6]  Irene Litvan,et al.  Lrrk2 and Lewy body disease , 2006, Annals of neurology.

[7]  P. S. St George-Hyslop,et al.  LRRK2 gene in Parkinson disease , 2005, Neurology.

[8]  J. Thomson,et al.  Embryonic stem cell lines derived from human blastocysts. , 1998, Science.

[9]  M. Cookson.  α-Synuclein and neuronal cell death , 2009, Molecular Neurodegeneration.

[10]  M. Zigmond,et al.  Wild-type LRRK2 but not its mutant attenuates stress-induced cell death via ERK pathway , 2008, Neurobiology of Disease.

[11]  D. German,et al.  Midbrain dopaminergic neurons in the mouse that contain calbindin-D28k exhibit reduced vulnerability to MPTP-induced neurodegeneration. , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[12]  E. Masliah,et al.  Alpha‐synuclein in Lewy Body Disease and Alzheimer's Disease , 1999, Brain pathology.

[13]  A. Hofman,et al.  Prognosis with Parkinson's disease in europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. , 2000, Neurology.

[14]  M. Tomishima,et al.  Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling , 2009, Nature Biotechnology.

[15]  H. Cai,et al.  Leucine-Rich Repeat Kinase 2 Regulates the Progression of Neuropathology Induced by Parkinson's-Disease-Related Mutant α-synuclein , 2009, Neuron.

[16]  C. Ross,et al.  Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  R. R. Reijo Pera,et al.  Enhanced Generation of Induced Pluripotent Stem Cells from a Subpopulation of Human Fibroblasts , 2009, PloS one.

[18]  C. Ross,et al.  Kinase activity of mutant LRRK2 mediates neuronal toxicity , 2006, Nature Neuroscience.

[19]  Rudolf Jaenisch,et al.  Parkinson's Disease Patient-Derived Induced Pluripotent Stem Cells Free of Viral Reprogramming Factors , 2009, Cell.

[20]  Tatiana Foroud,et al.  Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease , 2005, The Lancet.

[21]  R A Crowther,et al.  alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[22]  N. Hattori,et al.  Expression of the LRRK2 gene in the midbrain dopaminergic neurons of the substantia nigra , 2008, Neuroscience Letters.

[23]  A. Hofman,et al.  Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. , 2000, Neurology.

[24]  A. Abeliovich,et al.  The Familial Parkinsonism Gene LRRK2 Regulates Neurite Process Morphology , 2006, Neuron.

[25]  J. Langston,et al.  Can cellular models revolutionize drug discovery in Parkinson's disease? , 2009, Biochimica et biophysica acta.

[26]  Robert E. Burke,et al.  Pitx3 is required for development of substantia nigra dopaminergic neurons , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[27]  E. Blomme,et al.  Comparison of immunohistochemistry for activated caspase‐3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC‐3 subcutaneous xenografts , 2003, The Journal of pathology.

[28]  S E Ide,et al.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.

[29]  J. Trojanowski,et al.  Biochemical and pathological characterization of Lrrk2 , 2006, Annals of neurology.

[30]  M. Zigmond,et al.  Effects of 6‐hydroxydopamine on primary cultures of substantia nigra: specific damage to dopamine neurons and the impact of glial cell line‐derived neurotrophic factor , 2004, Journal of neurochemistry.

[31]  Takashi Aoi,et al.  Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts , 2008, Nature Biotechnology.

[32]  Andrew Lees,et al.  Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease , 2004, Neuron.

[33]  J Q Trojanowski,et al.  Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. , 1998, The American journal of pathology.

[34]  A. Simeone,et al.  Otx2 expression is restricted to dopaminergic neurons of the ventral tegmental area in the adult brain. , 2010, The International journal of developmental biology.

[35]  A. Kanthasamy,et al.  Proteasome inhibitor MG-132 induces dopaminergic degeneration in cell culture and animal models. , 2006, Neurotoxicology.

[36]  Colin L. Masters,et al.  α-Synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease β-amyloid plaque cores , 1999, Neuroscience Letters.

[37]  T. Sherer,et al.  Animal models of Parkinson's disease. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[38]  R. McKay,et al.  The foxa2 Gene Controls the Birth and Spontaneous Degeneration of Dopamine Neurons in Old Age , 2007, PLoS biology.

[39]  A. Storch,et al.  Emerging role of LRRK2 in human neural progenitor cell cycle progression, survival and differentiation , 2009, Molecular Neurodegeneration.

[40]  Philippe Amouyel,et al.  Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. , 2004, Lancet.

[41]  Kwang-Soo Kim,et al.  LRRK2 enhances oxidative stress-induced neurotoxicity via its kinase activity. , 2010, Experimental cell research.

[42]  T. Ichisaka,et al.  Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2007, Cell.

[43]  R. Crowther,et al.  α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .

[44]  L. Cantley,et al.  Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. , 2009, The Biochemical journal.

[45]  A. Singleton,et al.  alpha-Synuclein locus triplication causes Parkinson's disease. , 2003, Science.

[46]  D. Hernandez,et al.  The dardarin G2019S mutation is a common cause of Parkinson's disease but not other neurodegenerative diseases , 2005, Neuroscience Letters.

[47]  George Q. Daley,et al.  Disease-Specific Induced Pluripotent Stem Cells , 2008, Cell.

[48]  Timothy Lynch,et al.  Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. , 2005, American journal of human genetics.

[49]  P Falkai,et al.  Alpha-synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease beta-amyloid plaque cores. , 1999, Neuroscience letters.

[50]  W. H. Oertel,et al.  Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat , 1994, Neuroscience.

[51]  T. Dawson,et al.  Molecular Pathways of Neurodegeneration in Parkinson's Disease , 2003, Science.

[52]  H. Ichinose,et al.  Molecular cloning of the human Nurr1 gene: characterization of the human gene and cDNAs. , 1999, Gene.